NCT00606294View on ClinicalTrials.gov

Using Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission Tomography To Detect Hypoxia in Head and Neck Cancer Patients

NACompletedINTERVENTIONAL

Enrollment

216

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

August 31, 2019

Study Completion Date

June 9, 2023

Conditions

Head and Neck Cancer

Interventions

RADIATION

fluorine-18-labeled fluoro-misonidazole (18F-FMISO)

DEVICE

18F-FMISO PET scan

DEVICE

MRI

DEVICE

FDG PET/CT scan

Trial Locations (5)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11570

Memorial Sloan Kettering Cancer Center at Mercy Medical Center, Rockville Centre

11725

Memorial Sloan Kettering Cancer Center at Commack, Commack

Unknown

Memorial Sloan Kettering Cancer Center at Basking Ridge, Basking Ridge

All Listed Sponsors

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00606294 - Using Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission Tomography To Detect Hypoxia in Head and Neck Cancer Patients | Biotech Hunter | Biotech Hunter